Molecular characteristics and clinical outcomes of breast cancer with HRAS mutations

Authors:

Samuel Kareff, Estelamari Rodriguez, Richa Dawar, Asaad Trabolsi, Jesus Antonio Ocejo Gallegos, Jun Yin, Phillip Walker, Irene Kang, Matias A. Bustos, Josh Neman, Dave S Hoon, Stephanie L. Graff, David Spetzler, Gilberto Lopes

Background:

• Alterations in the RAS pathway are linked to tumorigenesis

• RAS alterations are currently under-studied in breast cancer (BC) compared to other solid tumors

• HRAS can be indirectly targeted with tipifarnib, a farnesyltransferase inhibitor

• We aimed to characterize the molecular characteristics and understand clinical outcomes of BC with HRAS mutations (HRASmut)

Download Publication